LX1

Overview

LX1 is an anti-prostate cancer compound that targets androgen receptor ( AR ), AR variants and steroidogenic enzyme AKR1C3 . LX1 inhibits the enzymatic activity of AKR1C3 , reduces the conversion of androstenedione to testosterone and reduces the expression of AR and AR-V7 and downregulates their target genes. LX1 overcomes the resistance of tumor cells to Enzalutamide ( HY-70002 ), and the combination with Enzalutamide ( HY-70002 ) further inhibits tumor growth.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance

Product Information

• Catalog No.: HY-163940
• CAS No.: 2647877-84-5
• Molecular Formula: C22H15F6NO2
• Molecular Weight: 439.35
• Purity: 99.13%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (11.38 mM); Clear solution
• Availability: In-stock

Source

Original product source